Skip to main content
. 2022 Sep 27;11(1):2315–2325. doi: 10.1080/22221751.2022.2117094

Figure 2.

Figure 2.

Efficacy of CT-P63 against SARS-CoV-2 Beta, Delta, and Omicron variants in an hACE2 transgenic mouse model. (A) Mean (SD) change in body weight after Beta variant infection. (B) Lung viral titres after Beta variant infection. (C) Nasal wash viral titres after Beta variant infection. (D) Mean (SD) change in body weight after Delta variant infection. (E) Lung viral titres after Delta variant infection. (F) Nasal wash viral titres after Delta variant infection. (G) Mean (SD) change in body weight after Omicron variant infection. (H) Lung viral titres after Omicron variant infection at Day 3 post-infection. (I) Nasal wash viral titres after Omicron variant infection at Day 3 post-infection.

Notes: In panel A, a denotes p < 0.001 between placebo and CT-P63 20 mg/kg group and p < 0.0001 between placebo and CT-P63 40 mg/kg group and b denotes p < 0.001 between placebo and CT-P63 20 mg/kg and 40 mg/kg groups. In panels B, C, D, E, F, G, H, and I *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001 relative to placebo, respectively.hACE2, human angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.